Skip to main content
ResearchTreatments

Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib

By June 21, 2021November 7th, 2021No Comments

*April 2021*

MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly understood. In this study, we investigated the mechanisms of acquired resistance to osimertinib and savolitinib by using pretreatment and post-treatment tissue analysis.